Good morning :)
Place Order
Add to Watchlist

Eris Lifesciences Ltd

ERIS Share Price

1,754.300.45% (+7.80)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹23,786 cr, stock is ranked 316

Stock is 2.68x as volatile as Nifty

ERIS Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹23,786 cr, stock is ranked 316

Stock is 2.68x as volatile as Nifty

ERIS Performance & Key Metrics

ERIS Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
67.517.270.42%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
37.436.450.81%

ERIS Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
90%
Analysts have suggested that investors can buy this stock

from 10 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

ERIS Company Profile

Eris Lifesciences Limited is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian Pharmaceutical Market

Investor Presentation

View older View older 

May 19, 2025

PDF
View Older Presentations

ERIS Similar Stocks (Peers)

Compare with peers Compare with peers 

ERIS Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
36.94
36.94
1Y Return
8.91%
8.91%
Buy Reco %
84.85
84.85
PE Ratio
22.73
22.73
1Y Return
1.73%
1.73%
Buy Reco %
68.75
68.75
PE Ratio
60.29
60.29
1Y Return
16.45%
16.45%
Buy Reco %
70.83
70.83
PE Ratio
55.89
55.89
1Y Return
23.38%
23.38%
Buy Reco %
81.25
81.25
PE Ratio
18.40
18.40
1Y Return
7.22%
7.22%
Buy Reco %
48.39
48.39
Compare with Peers

ERIS Forecast

ERIS Forecasts

Price

Revenue

Earnings

ERIS

ERIS

Income

Balance Sheet

Cash Flow

ERIS Income Statement

ERIS Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 21.85%, vs industry avg of 10.15%

Increasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.43% to 0.7%

Lower than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 3.48%, vs industry avg of 20.04%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue774.61882.011,013.851,089.461,220.571,373.131,743.832,080.112,926.992,912.06
Raw Materialssubtract107.73136.92167.12150.12276.44259.29348.53379.33749.461,876.44
Power & Fuel Costsubtract3.023.173.454.623.954.165.7012.0415.08
Employee Costsubtract131.22157.32190.66205.69229.30250.18346.16403.82505.09
Selling & Administrative Expensessubtract204.42224.28279.66238.82210.94256.10375.66422.92476.96
Operating & Other expensessubtract33.9711.81-3.80106.3060.4992.28119.88163.35144.78
Depreciation/Amortizationsubtract22.7625.6436.3550.2642.9964.71117.09182.51315.46314.67
Interest & Other Itemssubtract1.1010.6523.062.301.984.2226.1784.80231.29231.29
Taxes & Other Itemssubtract23.6018.1226.5634.8639.3636.0822.4839.29137.03137.29
EPS17.9521.3921.1521.7026.1529.8928.1128.8325.8525.88
DPS0.000.000.002.875.506.017.350.007.357.35
Payout ratio0.000.000.000.130.210.200.260.000.280.28

ERIS Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual report

PDF

Investor Presentation

May 19PDF
Feb 4PDF
Oct 25PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Aug 7PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

May 17PDF
Jan 17PDF
Oct 20PDF
Aug 5PDF
FY 2022FY 2022

Annual report

PDF

Investor Presentation

May 3PDF
Feb 2PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
 

ERIS Stock Peers

ERIS Past Performance & Peer Comparison

ERIS Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Eris Lifesciences Ltd67.617.270.42%
Sun Pharmaceutical Industries Ltd36.945.570.95%
Cipla Ltd22.733.831.08%
Torrent Pharmaceuticals Ltd60.2915.180.94%

ERIS Stock Price Comparison

Compare ERIS with any stock or ETF
Compare ERIS with any stock or ETF
ERIS
Loading...

ERIS Holdings

ERIS Shareholdings

ERIS Promoter Holdings Trend

ERIS Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

ERIS Institutional Holdings Trend

ERIS Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

ERIS Shareholding Pattern

ERIS Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding54.85%16.59%1.48%8.43%18.66%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

ERIS Shareholding History

ERIS Shareholding History

Dec '23MarJunSepDec '24Mar13.14%14.27%14.59%8.01%8.35%8.43%

Mutual Funds Invested in ERIS

Mutual Funds Invested in ERIS

No mutual funds holding trends are available

Top 5 Mutual Funds holding Eris Lifesciences Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
4.0638%2.84%0.04%6/89 (+1)
1.7411%1.67%0.17%17/123 (+46)
1.3215%2.25%0.04%6/106 (0)

Compare 3-month MF holding change on Screener

ERIS Insider Trades & Bulk Stock Deals

ERIS Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing ERIS stock

smallcases containing ERIS stock

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Eris Lifesciences Ltd

Loading...
Pharma Tracker

Pharma Tracker

Created by Windmill Capital

ERIS's Wtg.
9.14%
9.14%
CAGR
20.14%
Safe Haven Model

Safe Haven Model

Created by Windmill Capital

ERIS's Wtg.
9.46%
9.46%
CAGR
24.53%

ERIS Events

ERIS Events

ERIS Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

ERIS Dividend Trend

No dividend trend available

ERIS Upcoming Dividends

ERIS Upcoming Dividends

No upcoming dividends are available

ERIS Past Dividends

ERIS Past Dividends

Cash Dividend

Ex DateEx DateFeb 13, 2025

Interim
Interim | Div/Share: ₹7.35

Dividend/Share

7.35

Ex DateEx Date

Feb 13, 2025

Cash Dividend

Ex DateEx DateAug 11, 2022

Interim
Interim | Div/Share: ₹7.35

Dividend/Share

7.35

Ex DateEx Date

Aug 11, 2022

Cash Dividend

Ex DateEx DateAug 5, 2021

Interim
Interim | Div/Share: ₹6.01

Dividend/Share

6.01

Ex DateEx Date

Aug 5, 2021

Cash Dividend

Ex DateEx DateAug 13, 2020

Interim
Interim | Div/Share: ₹5.50

Dividend/Share

5.50

Ex DateEx Date

Aug 13, 2020

Cash Dividend

Ex DateEx DateMar 19, 2020

Interim
Interim | Div/Share: ₹2.87

Dividend/Share

2.87

Ex DateEx Date

Mar 19, 2020

ERIS Stock News & Opinions

ERIS Stock News & Opinions

Corporate
ERIS Lifesciences to conduct AGM

ERIS Lifesciences announced that the 19th Annual General Meeting(AGM) of the company will be held on 25 July 2025.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Spotlight
Eris Lifesciences gains after Q4 PAT climbs 32% YoY to Rs 94 cr

Profit before tax (PBT) climbed 67.9% YoY to Rs 128.87 crore in Q4 FY25. During the quarter EBITDA stood at Rs 252 crore, up 70% compared with Rs 148 crore posted in same quarter last year. EBITDA margin expanded to 35.8% in Q4 FY25 as against 26.9% in Q4 FY24. Revenue from domestic branded formulation (DBF) business jumped 25% YoY to Rs 602 crore in Q4 FY25. The organic base grew 10% to Rs 529 crore, while revenue from Biocon -2 stood at Rs 73 crore during the period under review. The company reported 22% organic growth in overall insulin revenue to Rs 300 crore despite significant product shortage in RHI throughout the year. On full year basis, the company's consolidated net profit declined 10.3% to Rs 351.84 crore on 44.6% increase in revenue from operations to Rs 2,879.26 crore in FY25 over FY24. On guidance front, for FY26, the company projects an annual revenue addition of Rs 200'300 crore to its overall insulin franchise, beginning October 2025, driven by the insourcing of insulin production at its Bhopal facility. This strategic move is expected to significantly enhance its insulin portfolio. In DBF business, the company anticipates revenue growth of 15% to 21%, translating to revenues in the range of Rs 2,900'3,050 crore. EBITDA for the segment is projected between Rs 1,070 crore and Rs 1,130 crore, with EBITDA margins maintained around 37%. Additionally, the company expects revenues from its Swiss Parentals division to range between Rs 375- 390 crore reflecting a growth of 15'20%. EBITDA for this segment is estimated between Rs 130 crore and Rs 135 crore, with an EBITDA margin of approximately 35%. The company plans to expand Eris-AMD, its new injectable facility, with a capital expenditure of Rs 100- 200 crore in FY26. Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products.Powered by Capital Market - Live

1 month agoCapital Market - Live
Live Market Update
Nifty fails to hold 24,900 level; realty shares jump

The key equity indices traded with limited losses in morning trade as investors engaged in mild profit booking despite supportive global cues. The Nifty traded below the 24,900 level. Market participants will closely monitor global trade developments and the ongoing Q4 earnings season, which are likely to influence sentiment in the coming days. Realty shares witnessed buying demand for fifth consecutive trading session. At 10:25 IST, the barometer index, the S&P BSE Sensex, declined 207.05 points or 0.25% to 81,852.37. The Nifty 50 index fell 44.90 points or 0.19% to 24,894.40. The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index fell 0.27% and the S&P BSE Small-Cap index shed 0.06%. The market breadth was positive. On the BSE, 1,772 shares rose and 1,729 shares fell. A total of 207 shares were unchanged. Buzzing Index: The Nifty Realty index advanced 1% to 942.55. The index rose 8.8% in the five consecutive trading sessions. DLF (up 5.29%), Raymond (up 4.95%), Sobha (up 0.55%), Prestige Estates Projects (up 0.36%) and Godrej Properties (up 0.09%) advanced. On the other hand, Phoenix Mills (down 1.16%), Macrotech Developers (down 1.01%) and Brigade Enterprises (down 0.91%) declined Stocks in Spotlight: Eris Lifesciences rallied 3.53% after the company reported a 30.29% jump in consolidated net profit to Rs 92.01 crore on 28.38% increase in revenue from operations to Rs 702.60 crore in Q4 FY25 over Q4 FY24. Ashok Leyland added 1.18% after the company's board is scheduled to meet on 23 May to consider the proposal for the issue of bonus shares. Adani Ports & Special Economic Zone (APSEZ) shed 0.18%. The company's board will meet on 23 May to consider issuing non-convertible debentures (NCDs) via a private placement basis.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
ERIS Lifesciences consolidated net profit rises 32.11% in the March 2025 quarter

Net profit of ERIS Lifesciences rose 32.11% to Rs 93.84 crore in the quarter ended March 2025 as against Rs 71.03 crore during the previous quarter ended March 2024. Sales rose 28.38% to Rs 702.60 crore in the quarter ended March 2025 as against Rs 547.27 crore during the previous quarter ended March 2024. For the full year,net profit declined 10.26% to Rs 351.84 crore in the year ended March 2025 as against Rs 392.05 crore during the previous year ended March 2024. Sales rose 44.59% to Rs 2879.26 crore in the year ended March 2025 as against Rs 1991.30 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales702.60547.27 28 2879.261991.30 45 OPM %35.9227.12 -35.3333.89 - PBDT206.12130.55 58 804.33613.85 31 PBT128.8776.75 68 488.87431.34 13 NP93.8471.03 32 351.84392.05 -10 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
ERIS Lifesciences to hold board meeting

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 19 May 2025.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Eris Lifesciences allots 33,287 equity shares under ESOP

Eris Lifesciences has allotted 33,287 equity shares under ESOP on 06 March 2025. The paid-up share capital of the Company accordingly stands increased from Rs. 13,61,29,282/- (13,61,29,282 equity shares of Re. 1/- each) to Rs. 13,61,62,569/- (13,61,62,569 equity shares of Re. 1/- each). Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Eris Lifesciences avails credit facility of Rs 1,000 cr

Eris Lifesciences has availed credit facilities amounting to Rs 1000 crore from Kotak Mahindra Bank (Bank). The aggregate debt level of the company would remain unchanged.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Board of ERIS Lifesciences recommends Interim Dividend

ERIS Lifesciences announced that the Board of Directors of the Company at its meeting held on 06 February 2025, has recommended a Interim dividend of Rs.7.35 per share (i.e.735%), subject to the approval of the shareholders.Powered by Capital Market - Live

5 months agoCapital Market - Live
Corporate
ERIS Lifesciences schedules board meeting

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 7 February 2025.Powered by Capital Market - Live

5 months agoCapital Market - Live
Earnings
ERIS Lifesciences consolidated net profit declines 18.60% in the December 2024 quarter

Net profit of ERIS Lifesciences declined 18.60% to Rs 83.63 crore in the quarter ended December 2024 as against Rs 102.74 crore during the previous quarter ended December 2023. Sales rose 49.36% to Rs 722.12 crore in the quarter ended December 2024 as against Rs 483.48 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales722.12483.48 49 OPM %34.6636.30 - PBDT197.36161.59 22 PBT116.16115.87 0 NP83.63102.74 -19 Powered by Capital Market - Live

5 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Eris Lifesciences Ltd (ERIS) today?

    The share price of ERIS as on 15th July 2025 is ₹1754.30. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Eris Lifesciences Ltd (ERIS) share?

    The past returns of Eris Lifesciences Ltd (ERIS) share are
    • Past 1 week: 1.53%
    • Past 1 month: -4.00%
    • Past 3 months: 26.96%
    • Past 6 months: 34.92%
    • Past 1 year: 72.79%
    • Past 3 years: 160.05%
    • Past 5 years: 296.72%

  3. What are the peers or stocks similar to Eris Lifesciences Ltd (ERIS)?
  4. What is the dividend yield % of Eris Lifesciences Ltd (ERIS) share?

    The current dividend yield of Eris Lifesciences Ltd (ERIS) is 0.42.

  5. What is the market cap of Eris Lifesciences Ltd (ERIS) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Eris Lifesciences Ltd (ERIS) is ₹23786.86 Cr as of 15th July 2025.

  6. What is the 52 week high and low of Eris Lifesciences Ltd (ERIS) share?

    The 52-week high of Eris Lifesciences Ltd (ERIS) is ₹1910 and the 52-week low is ₹987.10.

  7. What is the PE and PB ratio of Eris Lifesciences Ltd (ERIS) stock?

    The P/E (price-to-earnings) ratio of Eris Lifesciences Ltd (ERIS) is 67.61. The P/B (price-to-book) ratio is 7.27.

  8. Which sector does Eris Lifesciences Ltd (ERIS) belong to?

    Eris Lifesciences Ltd (ERIS) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Eris Lifesciences Ltd (ERIS) shares?

    You can directly buy Eris Lifesciences Ltd (ERIS) shares on Tickertape. Simply sign up, connect your demat account and place your order.